MedTrace Logo

European Safety Registry in Ulcerative Colitis (P04808)

NCT00705484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2239

Last updated 2018-08-27

Study results available
· View outcomes & findings →

Summary

This is a prospective, safety surveillance registry in participants with moderate-to-severe active ulcerative colitis (UC).

Conditions

Interventions

BIOLOGICAL

infliximab

The treating physician will determine the treatment regimen and dose of Remicade.

DRUG

Standard Therapy

The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-01
Primary Completion
2016-10-20
Completion
2016-10-20

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705484 on ClinicalTrials.gov